GN

Glomerulonephritis, commonly abbreviated as GN, is an inflammatory condition affecting the glomeruli, which are the microscopic filtering units within the kidneys responsible for removing waste products from the blood while retaining essential proteins and cells. Each kidney contains hundreds of thousands of glomeruli, and when these structures become inflamed and damaged, the kidney loses its ability to properly filter blood. The result is a progressive leakage of protein into the urine, a condition known as proteinuria, along with a gradual decline in overall kidney function.

The glomerulus consists of a specialized tuft of capillaries surrounded by a structure called Bowman's capsule. Blood flowing through these capillaries is filtered through a three-layered barrier comprising the capillary endothelium, the glomerular basement membrane, and the podocytes, which are specialized epithelial cells with foot-like projections that interdigitate to form filtration slits. In glomerulonephritis, immune complexes deposit within or adjacent to this filtration barrier, triggering an inflammatory response that damages the delicate structures and increases their permeability to proteins.

GN is one of the most common causes of chronic kidney disease in dogs and represents a significant clinical challenge because the disease is often advanced by the time clinical signs become apparent. Dogs have a remarkable ability to compensate for early kidney damage, and significant glomerular injury can occur before detectable changes in routine blood work emerge. This silent progression means that by the time a dog presents with signs of kidney disease, a substantial proportion of the glomeruli may already be irreversibly damaged.

The condition can occur as a primary disease process or, more commonly, as a secondary complication of another underlying condition. Infectious diseases, neoplasia, chronic inflammatory conditions, and endocrine disorders are among the many conditions that can trigger the immune-mediated processes leading to glomerular damage. Identifying and treating the underlying cause, when possible, is a critical component of managing glomerulonephritis effectively.

Glomerulonephritis in dogs is predominantly an immune-mediated condition in which the deposition of antigen-antibody complexes within the glomeruli triggers an inflammatory cascade that damages the filtration barrier. These immune complexes can form in two ways: circulating immune complexes may deposit in the glomeruli as blood passes through them, or antibodies may bind directly to antigens that are already present within the glomerular structures. Regardless of the mechanism, the result is activation of complement pathways and recruitment of inflammatory cells that cause progressive glomerular injury.

A wide range of underlying conditions can generate the persistent antigenemia that drives immune complex formation. Infectious diseases are among the most frequently identified triggers and include ehrlichiosis, borreliosis, leishmaniasis, dirofilariasis, chronic bacterial infections such as pyometra or endocarditis, and various fungal infections. The chronic antigenic stimulation produced by these infections leads to ongoing production of immune complexes that continuously deposit in the glomeruli, perpetuating the inflammatory cycle.

Neoplastic conditions represent another important category of underlying causes. Various tumors, including lymphoma, hemangiosarcoma, mast cell tumors, and others, can produce tumor-associated antigens that stimulate immune complex formation. The paraneoplastic nature of GN in these cases means that successful treatment of the underlying tumor may lead to improvement or resolution of the glomerular disease. Chronic inflammatory conditions such as pancreatitis, inflammatory bowel disease, systemic lupus erythematosus, and polyarthritis can similarly drive immune complex formation and glomerular deposition.

In a significant proportion of cases, no underlying cause can be identified despite thorough diagnostic investigation. These cases are classified as idiopathic glomerulonephritis and may represent primary immune-mediated disease in which the immune system targets glomerular components directly. Hereditary forms of glomerulonephritis have been identified in several breeds, including Bernese Mountain Dogs, Soft Coated Wheaten Terriers, English Cocker Spaniels, and Bull Terriers, in which genetic mutations affect the structure or function of glomerular components, predisposing them to immune-mediated damage.

The clinical presentation of glomerulonephritis in dogs can be subtle in the early stages and may go unnoticed by owners until the disease has progressed significantly. The earliest detectable abnormality is proteinuria, which is identified through urinalysis and urine protein quantification rather than through observable clinical signs. As protein loss through the kidneys increases and kidney function declines, dogs may begin to show nonspecific signs such as gradual weight loss, decreased appetite, and reduced energy levels that are easily attributed to aging or other benign causes.

As glomerulonephritis progresses and protein loss becomes more severe, dogs may develop nephrotic syndrome, a constellation of clinical findings that includes heavy proteinuria, low blood albumin levels (hypoalbuminemia), high blood cholesterol (hypercholesterolemia), and fluid accumulation in the body. The hypoalbuminemia results from the kidneys leaking albumin faster than the liver can produce it, and since albumin is the primary protein responsible for maintaining oncotic pressure within blood vessels, its depletion leads to fluid shifting out of the vasculature and into body cavities and tissues. This manifests as edema, particularly in the limbs and ventral abdomen, and as ascites, the accumulation of fluid within the abdominal cavity.

One of the most dangerous complications of glomerulonephritis is the development of thromboembolic disease. The loss of antithrombin III, a natural anticoagulant protein, through the damaged glomeruli creates a hypercoagulable state that significantly increases the risk of blood clot formation. Pulmonary thromboembolism is a feared complication that can present as sudden onset of respiratory distress, coughing, and collapse. Clots can also form in other locations including the portal vein, mesenteric vessels, and arteries of the limbs, potentially causing organ damage or limb ischemia.

In advanced cases where significant kidney damage has occurred, dogs may develop signs consistent with chronic kidney disease and uremia. These include markedly increased water consumption and urine production, vomiting, diarrhea, oral ulceration, ammonia-smelling breath, muscle wasting, and progressive weakness. Hypertension is a common complication of both glomerulonephritis and chronic kidney disease and can cause additional organ damage including retinal detachment and hemorrhage leading to sudden blindness, left ventricular hypertrophy, and further progression of kidney injury.

The diagnosis of glomerulonephritis involves a systematic approach that begins with detection of proteinuria and progresses through increasingly specific tests to characterize the nature and severity of the kidney disease and identify potential underlying causes. Routine urinalysis may reveal protein in the urine, but quantification requires measurement of the urine protein-to-creatinine ratio, which provides a standardized assessment of protein loss that is not affected by urine concentration. A urine protein-to-creatinine ratio greater than 2.0, particularly in the absence of urinary tract infection or inflammation, is highly suggestive of glomerular disease.

Blood work is essential for assessing the overall impact of glomerulonephritis on the dog's health. A serum biochemistry panel typically reveals hypoalbuminemia and may show elevated blood urea nitrogen and creatinine levels indicating reduced kidney function. Hypercholesterolemia is commonly observed and is part of the nephrotic syndrome complex. Measurement of antithrombin III levels helps assess the risk of thromboembolic complications. A complete blood count may reveal changes associated with chronic disease or underlying conditions, and coagulation testing can further characterize the hypercoagulable state.

Blood pressure measurement is an important component of the diagnostic evaluation, as systemic hypertension is a common finding in dogs with glomerulonephritis and can contribute to ongoing renal damage as well as damage to other organs. Multiple blood pressure readings should be obtained in a calm environment to minimize stress-related elevations. Abdominal ultrasound is performed to evaluate kidney size, shape, and architecture, and may reveal changes consistent with chronic kidney disease such as reduced kidney size, increased cortical echogenicity, or loss of normal corticomedullary distinction.

Renal biopsy is the gold standard for definitive diagnosis of glomerulonephritis and provides critical information about the type and severity of glomerular lesions, which has important prognostic and therapeutic implications. Biopsy specimens are evaluated using light microscopy, immunofluorescence, and electron microscopy. Light microscopy reveals the pattern of glomerular injury, such as membranous, membranoproliferative, or proliferative glomerulonephritis. Immunofluorescence identifies the types and patterns of immune complex deposition, while electron microscopy provides detailed structural information about the glomerular basement membrane and the location of immune deposits. The decision to perform a renal biopsy must be weighed against the procedural risks, including hemorrhage, and is typically reserved for cases where the information gained would significantly alter the treatment plan.

Treatment of glomerulonephritis in dogs involves a multimodal approach that addresses the underlying cause when identified, targets the immune-mediated inflammatory process, manages proteinuria and its consequences, and provides supportive care for declining kidney function. The treatment plan must be individualized based on the severity of the disease, the presence of complications, and the results of diagnostic testing including, when available, renal biopsy findings.

When an underlying cause of glomerulonephritis is identified, directed treatment of that condition is the highest priority. This may involve antimicrobial therapy for infectious diseases, surgical or chemotherapeutic treatment of neoplasia, or management of chronic inflammatory conditions. Resolution of the underlying antigenic stimulus can lead to cessation of immune complex deposition and improvement in glomerular function, though established structural damage may be irreversible. In cases where no underlying cause is found or where the underlying condition cannot be eliminated, immunosuppressive therapy may be considered, though its efficacy in canine glomerulonephritis remains debated.

Antiproteinuric therapy is a cornerstone of GN management regardless of the underlying cause. Angiotensin-converting enzyme inhibitors such as enalapril or benazepril, and angiotensin receptor blockers such as telmisartan, are used to reduce intraglomerular pressure and decrease protein leakage through the damaged filtration barrier. These medications work by dilating the efferent arteriole of the glomerulus, reducing the pressure gradient across the filtration barrier. Dietary protein modification, typically in the form of high-quality protein provided in moderate amounts, helps reduce the protein load presented to damaged glomeruli while maintaining adequate nutrition.

Antithrombotic therapy is critically important in dogs with significant proteinuria due to the high risk of thromboembolic complications. Low-dose aspirin or clopidogrel is commonly prescribed to reduce platelet aggregation, and some clinicians advocate for the use of anticoagulants such as rivaroxaban or low-molecular-weight heparin in dogs with severely decreased antithrombin III levels. Management of hypertension with antihypertensive medications, treatment of edema and ascites with judicious diuretic use, and management of hyperlipidemia with dietary modification or medications such as omega-3 fatty acids round out the comprehensive treatment approach.

The prognosis for dogs with glomerulonephritis is highly variable and depends on several factors, including the underlying cause, the type and severity of glomerular lesions, the degree of proteinuria, the presence of azotemia at diagnosis, and the response to treatment. In general, GN is considered a serious condition that can progress to end-stage renal failure, though the timeline of this progression varies considerably. Dogs in which an underlying cause is identified and successfully treated tend to have a more favorable outlook than those with idiopathic disease.

The degree of proteinuria at diagnosis and its response to antiproteinuric therapy are important prognostic indicators. Dogs with very high urine protein-to-creatinine ratios and those in which proteinuria does not respond adequately to treatment are at greater risk for progressive renal deterioration. Similarly, dogs that present with azotemia, indicating that significant nephron loss has already occurred, generally have a more guarded prognosis than those diagnosed before kidney function has measurably declined. The presence of nephrotic syndrome and its complications, particularly thromboembolic disease, also worsens the prognosis.

Renal biopsy findings, when available, provide valuable prognostic information. Certain histological patterns of glomerulonephritis carry a worse prognosis than others. Membranoproliferative glomerulonephritis and glomerulonephritis with significant tubulointerstitial fibrosis and glomerulosclerosis tend to be associated with more aggressive disease progression. Amyloidosis, another cause of glomerular protein loss that can be confused with GN clinically, generally carries a poor prognosis. The degree of chronic irreversible changes seen on biopsy helps determine how much functional recovery is realistically achievable.

Long-term management requires regular monitoring to assess treatment efficacy and detect disease progression. Serial measurement of urine protein-to-creatinine ratio, serum creatinine, blood urea nitrogen, albumin, and blood pressure allows the veterinary team to adjust therapy as needed. Dogs that achieve good control of proteinuria and maintain stable kidney function can live for months to years with appropriate management, while those with progressive disease may eventually require end-of-life decisions based on quality-of-life assessments.

Several dog breeds have been identified as having a genetic predisposition to glomerulonephritis or related glomerular diseases, and understanding these breed associations can aid in early detection and proactive monitoring. The Bernese Mountain Dog has a well-documented hereditary form of glomerulonephritis that tends to present in young to middle-aged dogs. Affected Bernese Mountain Dogs develop progressive proteinuria and kidney disease, and the condition has been linked to specific genetic factors within the breed. Breeders and owners of Bernese Mountain Dogs should be aware of this predisposition and consider regular urinalysis screening.

The Soft Coated Wheaten Terrier is affected by a familial protein-losing nephropathy and enteropathy that represents a significant health concern within the breed. The renal component of this condition involves glomerular disease that leads to heavy proteinuria and progressive kidney failure. The condition tends to present in middle-aged dogs and can be accompanied by a concurrent protein-losing intestinal disease, creating a complex clinical picture. Breed-specific research efforts and registries have been established to better understand the genetic basis and improve early detection.

English Cocker Spaniels are predisposed to a hereditary nephropathy that involves glomerular and tubulointerstitial disease. The condition tends to present in young dogs and can progress to renal failure. Bull Terriers are affected by a hereditary nephritis that has been well characterized and involves a defect in the type IV collagen of the glomerular basement membrane, analogous to Alport syndrome in humans. This condition is inherited in an autosomal dominant pattern and leads to progressive kidney disease, typically becoming clinically apparent in early to middle adulthood.

Samoyeds are affected by a hereditary nephritis caused by a mutation in the gene encoding the alpha-5 chain of type IV collagen, which is a critical structural component of the glomerular basement membrane. This X-linked condition predominantly affects male dogs, with affected males developing progressive kidney disease and typically reaching end-stage renal failure by one to two years of age. Female carriers may show mild proteinuria but generally do not develop severe kidney disease. Doberman Pinschers, Rottweilers, and Greyhounds have also been reported to have increased susceptibility to glomerular disease, though the specific genetic mechanisms in these breeds are less well characterized.

Dietary management plays a vital role in the comprehensive treatment of dogs with glomerulonephritis and must be carefully tailored to address the complex metabolic derangements associated with the disease. The goals of dietary therapy include reducing the protein load on damaged glomeruli, maintaining adequate nutrition despite protein losses, managing complications such as hyperlipidemia and hypertension, and supporting overall kidney function. The approach to nutrition in GN patients has evolved significantly as understanding of the disease has improved, moving away from severe protein restriction toward a more nuanced strategy.

Protein management in dogs with GN requires balancing the need to reduce proteinuria with the requirement to maintain lean body mass in the face of ongoing urinary protein losses. Current recommendations favor feeding moderate amounts of high-quality, highly bioavailable protein rather than severely restricting protein intake. Excessive protein restriction can lead to muscle wasting, immune dysfunction, and poor wound healing, which are particularly problematic in dogs already dealing with hypoalbuminemia. Commercially available veterinary renal diets are formulated to provide appropriate protein levels along with other modifications beneficial for kidney disease.

Omega-3 fatty acid supplementation, particularly with eicosapentaenoic acid and docosahexaenoic acid derived from fish oil, is a widely recommended dietary intervention for dogs with glomerulonephritis. These fatty acids have anti-inflammatory properties and have been shown to reduce glomerular inflammation, decrease proteinuria, and lower blood lipid levels in dogs with kidney disease. The recommended dose is typically higher than that used for general health supplementation, and high-quality marine-source omega-3 products are preferred to ensure adequate intake of the active fatty acid forms.

Sodium restriction is an important dietary consideration for dogs with GN, particularly those with hypertension or edema. Reducing dietary sodium helps lower blood pressure and decrease fluid retention. Phosphorus restriction becomes increasingly important as kidney function declines, as the kidneys' ability to excrete phosphorus diminishes, leading to hyperphosphatemia that contributes to further kidney damage through secondary hyperparathyroidism and soft tissue mineralization. Ensuring adequate caloric intake is essential, as dogs with GN may have reduced appetite due to uremia or medication side effects, and insufficient caloric intake leads to catabolism of muscle tissue for energy, further depleting protein stores.

Glomerulonephritis can give rise to several serious complications that may require emergency intervention, and owners of affected dogs should be educated about the warning signs that necessitate immediate veterinary attention. Thromboembolism is arguably the most life-threatening acute complication, with pulmonary thromboembolism representing a particularly dangerous event. Dogs experiencing a pulmonary embolism may present with sudden onset of severe respiratory distress, rapid and labored breathing, cyanosis, coughing, and collapse. This is a veterinary emergency requiring immediate stabilization with oxygen therapy and anticoagulant treatment.

Acute decompensation of kidney function can occur in dogs with GN, sometimes triggered by dehydration, concurrent illness, nephrotoxic drug exposure, or urinary tract obstruction. Signs of acute uremic crisis include severe vomiting, complete loss of appetite, profound lethargy, oral ulceration, seizures, and in severe cases, coma. Dogs experiencing an acute deterioration in kidney function may require hospitalization for intravenous fluid therapy to correct dehydration and support kidney perfusion, anti-nausea medications, and management of electrolyte abnormalities including potentially life-threatening hyperkalemia.

Hypertensive crisis, while less common, can occur in dogs with GN and may result in sudden blindness due to retinal detachment or hemorrhage, neurological signs including seizures and disorientation from cerebral edema, and acute worsening of kidney function. Blood pressure monitoring should be a routine part of follow-up care for dogs with GN, and antihypertensive therapy should be adjusted promptly if elevated readings are detected. Owners should be aware that sudden changes in vision, unexplained seizure activity, or acute neurological signs may indicate a hypertension-related emergency.

Severe hypoalbuminemia can lead to life-threatening fluid shifts, with progressive abdominal distension from ascites and severe peripheral edema that can impair mobility and skin integrity. In extreme cases, fluid accumulation in the chest cavity (pleural effusion) can compromise breathing. While diuretic therapy can help manage fluid accumulation, overly aggressive diuresis carries the risk of volume depletion and further compromise of kidney perfusion. Therapeutic abdominocentesis, the careful removal of abdominal fluid, may be necessary in cases of severe ascites causing respiratory compromise or significant discomfort.

Research into canine glomerulonephritis continues to advance across multiple fronts, with ongoing efforts to improve diagnostic capabilities, refine treatment protocols, and develop novel therapeutic approaches. One significant area of progress involves the application of advanced histopathological techniques to better classify glomerular lesions and predict clinical outcomes. The development of standardized reporting guidelines for canine renal biopsies, modeled after similar systems in human nephrology, has improved consistency in diagnosis and facilitated comparisons across research studies.

The field of veterinary nephrology has seen growing interest in biomarker research aimed at identifying glomerular disease earlier in its course, before significant and irreversible damage has occurred. Novel urinary biomarkers, including immunoglobulin G, transferrin, retinol-binding protein, and various cytokines, are being investigated for their ability to detect glomerular damage before traditional markers such as urine protein-to-creatinine ratio become elevated. Earlier detection could enable intervention at a stage when the disease is more amenable to treatment and renal function preservation.

Immune-targeted therapies represent a promising avenue for future treatment of GN. As understanding of the specific immunological pathways involved in canine glomerulonephritis improves, more targeted immunomodulatory agents may become available. Mycophenolate mofetil, which selectively inhibits lymphocyte proliferation, has shown promise in some cases of immune-mediated GN and is being studied more extensively. Research into biologics and monoclonal antibodies that target specific components of the immune response involved in glomerular damage is in earlier stages but holds significant potential for more effective and less toxic treatment options.

Genetic research continues to unravel the hereditary basis of glomerulonephritis in predisposed breeds. Identification of specific causative mutations enables the development of genetic tests that breeders can use to make informed decisions and reduce the prevalence of hereditary GN within affected breeds. Beyond breeding applications, understanding the genetic defects responsible for hereditary forms of GN provides insight into the fundamental mechanisms of glomerular disease that may be applicable to acquired forms as well. Collaborative research efforts involving breed clubs, veterinary teaching hospitals, and specialized research laboratories are accelerating the pace of discovery in this important area of veterinary medicine.